ISRCTN58955026已完成未知
Treating neovascular age-related Macular degeneration with Aflibercept: a pilot 24-month, multi-centre randomized controlled trial comparing standard care with an individualised Treat and Extend regimen
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 50 years or above
- •2. Able to provide written, informed consent to the study
- •3. Able and willing to attend for hospital visits at the frequency required
- •4. Visual impairment predominantly due to neovascular age–related macular degeneration (AMD).
- •5. Active, treatment naive, angiographically active choroidal neovascular membrane in the study eye secondary to neovascular AMD with any part of the lesion or its sequelae (e.g. sub retinal fluid, intra retinal fluid, haemorrhage, pigment epithelial detachment, sub retinal pigment epithelium(RPE) fluid) in a sub foveal location
- •6. Visual acuity of 7824 ETDRS letters at screening and baseline in the study eye.
- •7. If both eyes are eligible at baseline, the worst seeing eye will be included in the study although the final decision will rest with the investigator. Any deviation from entering the worst seeing eye into the study will be explained and documented in the patient notes and the CRF. The choice of eye selected for inclusion into the study will be determined and documented before the patient is randomised. A patient who has both eyes that may be eligible may therefore undergo a different treatment regimen in each eye, however they will be treated with aflibercept in both eyes. Hospital visits will be co-ordinated to minimise the number of attendances required and therefore the inconvenience for the patient.
排除标准
- •1. Inability to comply with the study or follow up procedures
- •2. Pregnant or lactating women
- •3. Women of child bearing potential unless they are using effective methods of contraception (total abstinence, female or male sterilization, barrier contraception, intrauterine device, oral or injectable hormonal methods of contraception)
- •4. Previous treatment for choroidal neovascularisation in the study eye
- •5. Fibrosis consisting of more than 50% of the lesion or involving the centre of the fovea
- •6. Coexisting pathology within 0.5 disc diameters of the fovea that could prevent an improvement in visual acuity in the opinion of the investigator (e.g. macular hole, dense epi - retinal membrane)
- •7. Cataract (causing significant visual impairment), aphakia, vitreous haemorrhage, retinal detachment, proliferative retinopathy or CNV due to any cause other than AMD at screening and baseline
- •8. Known allergy to aflibercept or fluorescein
- •9. History of cerebrovascular accident, transient ischemic attack or myocardial infarction within 3 months of the screening visit
- •10. Any type of systemic disease or treatment that may affect or expect to affect the clinical status of the patient to a significant degree
- •11. Blood pressure of >160mmHg systolic or >100mmHg diastolic at screening or baseline
- •12. Any active periocular infection or inflammation at screening or baseline
- •13. Uncontrolled glaucoma (30mmHg) at screening or baseline
- •14. Neovascularisation of the iris at screening or baseline
- •15. Treatment with any anti angiogenic drugs to either eye within 3 months of baseline
- •16. Nd-YAG laser capsulotomy within the last 2 months or expected within 6 months of baseline in the affected eye
- •17. Use of other investigational drugs within 30 days
- •18. Use of systemic anti –vascular endothelial growth factor agents within 3 months prior to baseline
- •19. Use of systemic corticosteroids for at least 30 consecutive days within the 3 months prior to baseline
- •20. Current or planned medications known to be toxic to the lens, retina or optic nerve e.g. hydroxychloroquine, desferoxamine, tamoxifen or ethambutol
研究者
相似试验
进行中（未招募）
1 期
The MATE studyEUCTR2015-002302-36-GBYork Teaching Hospital40
进行中（未招募）
不适用
Treatment of neovascular age related macular degeneration with intravitreal Bevacizumab (Avastin)neovascular age-related macular degenerationEUCTR2006-001914-34-DEBert Mueller, Dep. Ophthalmology
进行中（未招募）
1 期
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)EUCTR2014-003132-39-FRBayer HealthCare AG268
进行中（未招募）
1 期
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)EUCTR2014-003132-39-GBBayer AG287
进行中（未招募）
1 期
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)EUCTR2014-003132-39-ESBayer HealthCare AG268